Pharma BD Deal Intelligence
Cerevel's $445M SPAC listing at a $1.3B valuation paid off big on paper — AbbVie bought it for $8.7B after tavapadon hit its Phase 3 endpoint — but emraclidine, the asset carrying the bulk of that value, failed both Phase 2 schizophrenia trials.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Karuna Therapeutics reported positive Phase 2 EMERGENT-1 results for KarXT (xanomeline-trospium) in acute schizophrenia, sending shares up 70%. The xanomeline…
Cerevel Therapeutics will go public through a merger with ARYA Sciences Acquisition Corp II in a deal valuing the CNS biotech at $1.3 billion pro forma. Gross…
Emraclidine did not meet primary endpoints in Phase 2 EMPOWER-1 and EMPOWER-2; no significant PANSS reduction vs placebo.
Source summaries from our enrichment pipeline; follow links for originals.
All 17 sources with sentiment breakdown →
Cerevel Therapeutics, the 2018 Pfizer-Bain Capital neuroscience spin-out, completed a SPAC merger with ARYA Sciences Acquisition Corp II raising $445M and listing on Nasdaq at ~$1.3B valuation. Pfizer retained equity stake. Pipeline included tavapadon for Parkinson's, CVL-231 for schizophrenia, and darigabat for epilepsy/anxiety. Post-close arc: the platform thesis largely played out. In April 2024 lead Parkinson's asset tavapadon hit its primary endpoint in the Phase 3 adjunctive TEMPO-3 trial. On August 1, 2024 AbbVie completed its acquisition of Cerevel for $45.00 per share (announced December 6, 2023; ~$8.7B equity value) — roughly a 6.7x step-up from the 2020 ~$1.3B SPAC valuation. However, in November 2024 AbbVie disclosed that emraclidine (CVL-231), the M4 PAM that carried the bulk of the pipeline's expected value, failed both Phase 2 EMPOWER schizophrenia trials, showing no statistically significant PANSS separation from placebo — a material impairment to the deal's central schizophrenia thesis.
Assessment window: 5yr post-close.
930K US cases/yr · $35.0B US CNS therapeutics market 2020 (USD MM, IQVIA) · 3400000 US adults with epilepsy
Cerevel's pipeline targets four major neuropsychiatric and neurodegenerative diseases. Parkinson's disease (PD) affects approximately 930,000 Americans (Parkinson's Foundation 2020) with ~60,000 new diagnoses annually; the standard-of-care levodopa loses durable efficacy and induces motor fluctuations and dyskinesias within 5-7 years, creating substantial unmet need for non-dopaminergic adjuncts and dopamine receptor partial agonists. Schizophrenia affects roughly 2.4 million US adults (NIMH 2020), with ~25-30% treatment-resistant to existing dopamine D2 antagonist antipsychotics, which carry significant metabolic and extrapyramidal liabilities. Epilepsy affects 3.4 million Americans (CDC 2020), with ~30-40% pharmacoresistant despite ~25 approved antiepileptic drugs. Anxiety disorders affect ~40 million US adults (NIMH); benzodiazepines remain effective but are limited by tolerance, dependence and cognitive side effects. The collective US TAM for CNS therapeutics exceeded $35B in 2020 (IQVIA), but the field had endured a decade of high-profile R&D failures across Alzheimer's (BACE inhibitors, anti-amyloid mAbs pre-Aduhelm), depression (NMDA modulators) and schizophrenia (TAAR1, mGluR2/3) — making subtype-selective receptor modulation a renewed point of investor interest.
Cerevel's lead asset tavapadon (CVL-751) is a dopamine D1/D5 partial agonist for early Parkinson's disease — a mechanism distinct from levodopa (precursor) and ropinirole/pramipexole (D2/D3 full agonists). Direct mechanistic competitors are limited: PharmaTher's Ketamir and Sun Pharma's Anavex 2-73 (sigma-1) take different paths. Broader PD pipeline includes Lundbeck's foliglurax (mGluR4 PAM, terminated 2020), AbbVie's prodopamine ABBV-951, Sage Therapeutics' SAGE-718 (NMDA PAM for cognition), and gene therapy approaches from Voyager (VY-AADC for advanced PD), Sangamo and Prevail Therapeutics (LRRK2). For schizophrenia, CVL-231 (now emraclidine, M4 muscarinic positive allosteric modulator) competes with Karuna Therapeutics' KarXT (xanomeline-trospium combo, M1/M4 agonist, Phase 3 EMERGENT-2/3) — Karuna IPO'd June 2019 and reported positive EMERGENT-1 Phase 2 data in late 2019. Sumitomo Dainippon's ulotaront (TAAR1, Phase 2/3) and Acadia's Nuplazid (pimavanserin, 5-HT2A inverse agonist for PD psychosis) round out non-D2 mechanisms. For epilepsy/anxiety, darigabat (CVL-865, GABA-A α2/3/5-selective partial PAM) competes with SK Biopharm's cenobamate (Xcopri, FDA-approved 2019), UCB's brivaracetam (Briviact), Marinus's ganaxolone (Phase 3 for CDKL5), and Sage's zuranolone (GABA-A PAM, MDD/PPD).
Cerevel reported positive topline results: a statistically significant increase in 'on' time without troublesome dyskinesia vs placebo as adjunct to levodopa.
AbbVie closed its acquisition of Cerevel (announced 2023-12-06) at $45.00 per share, ~$8.7B equity value — ~6.7x the 2020 ~$1.3B SPAC valuation.
AbbVie disclosed emraclidine did not meet primary endpoints in EMPOWER-1/-2; no significant PANSS separation from placebo — impairing the deal's lead schizophrenia asset.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cerevel Therapeutics / ARYA Sciences Acquisition Corp II (this deal) | 2020 | $445M | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
← Browse all deals · How we score deals
More: 2020 deals · Neurology deals